Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AKEBIA THERAPEUTICS, INC.

(AKBA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
2(c) 2.07(c) 2.03(c) 1.97(c) 1.83(c) Last
4 376 690 5 062 438 3 265 189 2 986 269 3 099 063 Volume
-1.96% +3.50% -1.93% -2.96% -7.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 205 M - -
Net income 2021 -270 M - -
Net cash position 2021 133 M - -
P/E ratio 2021 -1,07x
Yield 2021 -
Sales 2022 253 M - -
Net income 2022 -145 M - -
Net cash position 2022 102 M - -
P/E ratio 2022 -2,53x
Yield 2022 -
Capitalization 320 M 320 M -
EV / Sales 2021 0,91x
EV / Sales 2022 0,86x
Nbr of Employees 380
Free-Float 99,0%
More Financials
Company
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of... 
More about the company
Ratings of Akebia Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about AKEBIA THERAPEUTICS, INC.
01/27Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (..
BU
01/24AKEBIA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/20Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ..
AQ
01/10Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference
PR
01/05Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
01/04Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
01/04Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
PR
2021AKEBIA THERAPEUTICS, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
2021Akebia Therapeutics, Inc. Appoints Ron Frieson to Its Nominating and Corporate Governan..
CI
2021Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
2021Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
2021Akebia Therapeutics Announces Participation in Upcoming Investor Conferences
PR
2021Akebia Therapeutics to Present at Jefferies London Healthcare Conference
PR
2021PLAUSIBILITY AND UNDUE BURDEN : A New Look Insufficiency After FibroGen v Akebia
AQ
2021HC Wainwright Adjusts Akebia Therapeutics' Price Target to $10 From $6, Keeps Buy Ratin..
MT
More news
News in other languages on AKEBIA THERAPEUTICS, INC.
2021Akebia Therapeutics réduit sa perte nette au 3e trimestre, baisse du chiffre d'affaires..
2021Earnings Flash (AKBA) AKEBIA THERAPEUTICS affiche un chiffre d'affaires de 48,8 million..
2021Le partenaire d'Akebia, Otsuka, dépose une première AMM pour le vadadustat auprès de l'..
2021Les actions du secteur de la santé en baisse lundi en fin de journée
2021Les actions du secteur de la santé à la dérive lundi alors que les biotechnologies grim..
More news
Analyst Recommendations on AKEBIA THERAPEUTICS, INC.
More recommendations
Chart AKEBIA THERAPEUTICS, INC.
Duration : Period :
Akebia Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKEBIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 1,83 $
Average target price 7,17 $
Spread / Average Target 292%
EPS Revisions
Managers and Directors
John P. Butler Director
David A. Spellman Chief Financial Officer, Treasurer & Senior VP
Adrian Adams Chairman
Steven K. Burke Chief Medical Officer & Senior Vice President
Michel Dahan Chief Operating Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AKEBIA THERAPEUTICS, INC.-19.03%320
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325